A comprehensive model of predictors of quality of life in older adults with schizophrenia: results from the CSA study

Hoertel, Nicolas; Rotenberg, Léa; Blanco, Carlos; Camus, Vincent; Dubertret, Caroline; Charlot, Véronique; Schürhoff, Franck; Vandel, Pierre; Limosin, Frédéric; Adès, J.; Alezrah, Charles; Amado, Isabelle; Amar, G.; Andrei, Oana Cella; Arbault, D.; Archambault, Gary; Aurifeuille, G.; Barrière, Sarah; Béra-Potelle, Céline; Blumenstock, Yvonne; Bardou, H.; Bareil-Guérin, M.; Barrau, P.; Barrouillet, C.; Baup, E.; Bazin, Nadine; Beaufils, B.; Ayed, J. Ben; Benoît, Maryse; Benyacoub, K.; Bichet, T.; Blanadet, F.; Blanc, O.; Blanc-Comiti, J.; Boussiron, Didier; Bouysse, A.-M.; Brochard, A; Brochart, O.; Bucheron, B.; Cabot, M.; Chabannes, J.-M.; Charpeaud, Thomas; Clad-Mor, C.; Combes, Céline; Comisu, M.; Cordier, B.; Cormier, Lauren; Costi, F.; Courcelles, J. P.; Creixell, M.; Cuché, H; Cuervo-Lombard, Christine-Vanessa; Dammak, A; Rin, D. Da; Denis, JB; Denizot, H.; Deperthuis, A.; Diers, E.; Dirami, S.; Donneau, D.; Dreano, P.; Duprat, E.; Duthoit, Didier; Fernandez, Christine; Fonfrede, P.; Freitas, Noélle de Oliveira; Gasnier, P.; Gauillard, J.; Getten, F.; Gierski, Fabien; Godart, François; Gourévitch, Raphaël; Delyle, A. Grassin; Gremion, J.; Griner, Véronique; Guérin-Langlois, Christophe; Guggiari, C.; Guillin, Olivier; Hadaoui, H.; Haffen, E.; Hanon, Cécile; Haouzir, S.; Hazif‐Thomas, Cyril; Heron, A.; Hubsch, B.; Jalenques, Isabelle; Januel, Dominique; Kaladjian, Arthur; Karnycheff, J. F.; Kébir, Oussama; Krebs, M O; Lajugie, Christine; Leboyer, Marion; Legrand, P.; Lejoyeux, Michel; Lemaire, Vincent; Leroy, E.; Lévy-Chavagnat, Diane; Leydier, A.; Liling, C.; Llorca, P.M.; Loeffel, P.; Louville, P.; Lucas, Stéphane; Mages, N.; Mahi, M.; Maillet, Olivier; Manetti, Aude; Martelli, Catherine; Martín, Pilar Barreto; Masson, Marjolaine; Maurs-Ferrer, I.; Mauvieux, J.; Mazmanian, S.; Mechin, E.; Mekaoui, Lila; Meniai, M.; Metton, A.; Mihoubi, Alain; Mirón, María Luisa Limón; Mora, G; Ades, Veronica; Nubukpo, Philippe; Omnès, Cécile; Papin, Stéphanie; Paris, P.; Passerieux, Christine; Pellerin, J.; Perlbarg, Julie; Perron, Stéphane; Petit, Ariane; Petitjean, François; Portefaix, Christophe; Pringuey, D.; Radtchenko, A.; Rahiou, H.; Raucher‐Chéné, Delphine; Rauzy, Antoine; Reinheimer, L.; Renard, M; René, Margaux; Rengade, C.-E.; Reynaud, Philippe; Robin, Donald A.; Rodrigues, Christelle; Rollet, A.; Rondepierre, Fabien; Rousselot, B.; Rubingher, S.; Saba, Ghassen; Salvarelli, J.P.; Samuelian, J. C.; Sánchez‐Rico, Marina; Scemama-Ammar, C.; Schuster, J P; Sechter, D.; Segalas, B.; Seguret, T.; Seigneurie, Anne-Sophie; Semmak, A.; Slama, Frédéric; Taisne, S.; Taleb, M; Terra, J. L.; Thefenne, D.; Tran, Eric; Tourtauchaux, R.; Vacheron, M.N.; Vanhoucke, V.; Venet, E.; Verdoux, Hélène; Viala, A; Vidon, Gilles; Vitre, M. T.; Vurpas, JL; Wagermez, C.; Walter, Michel; Yon, Liova; Zendjidjian, X.

doi:10.1007/s00127-020-01880-2

Cited by 11 publications

(15 citation statements)

References 112 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They also indicate that patients taking a FIASMA antidepressant may have a significantly reduced risk of intubation or death compared with those taking a non-FIASMA antidepressant. These results suggest that the acid sphingomyelinase (ASM)/ceramide system may provide a useful framework for better understanding SARS-CoV-2 infection and the repurposing of FIASMA psychotropic medications, especially FIASMA antidepressants that are better tolerated than FIASMA antipsychotics [31][32][33]50], against COVID-19 among individuals with psychiatric disorders. Our findings also support the urgent need of double-blind controlled randomized clinical trials of these medications for COVID-19 in this population, and especially FIASMA antidepressants such as fluoxetine, fluvoxamine or escitalopram, and more broadly in patients with severe COVID-19.…”

Section: Discussionmentioning

confidence: 99%

“…Taken together, these preclinical, observational, and clinical findings suggest that the ASM/ceramide system may provide a useful framework for better understanding SARS-CoV-2 infection [9], the antiviral and anti-inflammatory effects of functional inhibitors of the ASM [9], and the repurposing of FIASMA psychotropic medications [6,7], whose short-term use is generally well-tolerated [31][32][33], against COVID-19.…”

Section: Introductionmentioning

confidence: 95%

See 1 more Smart Citation

Association between FIASMA psychotropic medications and reduced risk of intubation or death in individuals with psychiatric disorders hospitalized for severe COVID-19: an observational multicenter study

et al. 2022

Self Cite

View full text Add to dashboard Cite

The acid sphingomyelinase (ASM)/ceramide system may provide a useful framework for better understanding SARS-CoV-2 infection and the repurposing of psychotropic medications functionally inhibiting the acid sphingomyelinase/ceramide system (named FIASMA psychotropic medications) against COVID-19. We examined the potential usefulness of FIASMA psychotropic medications in patients with psychiatric disorders hospitalized for severe COVID-19, in an observational multicenter study conducted at Greater Paris University hospitals. Of 545 adult inpatients, 164 (30.1%) received a FIASMA psychotropic medication upon hospital admission for COVID-19. We compared the composite endpoint of intubation or death between patients who received a psychotropic FIASMA medication at baseline and those who did not in time-to-event analyses adjusted for sociodemographic characteristics, psychiatric and other medical comorbidity, and other medications. FIASMA psychotropic medication use at baseline was significantly associated with reduced risk of intubation or death in both crude (HR = 0.42; 95%CI = 0.31–0.57; p < 0.01) and primary inverse probability weighting (IPW) (HR = 0.50; 95%CI = 0.37–0.67; p < 0.01) analyses. This association was not specific to one FIASMA psychotropic class or medication. Patients taking a FIASMA antidepressant at baseline had a significantly reduced risk of intubation or death compared with those taking a non-FIASMA antidepressant at baseline in both crude (HR = 0.57; 95%CI = 0.38–0.86; p < 0.01) and primary IPW (HR = 0.57; 95%CI = 0.37–0.87; p < 0.01) analyses. These associations remained significant in multiple sensitivity analyses. Our results show the potential importance of the ASM/ceramide system framework in COVID-19 and support the continuation of FIASMA psychotropic medications in these patients and the need of large- scale clinical trials evaluating FIASMA medications, and particularly FIASMA antidepressants, against COVID-19.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 95%

Association between FIASMA psychotropic medications and reduced risk of intubation or death in individuals with psychiatric disorders hospitalized for severe COVID-19: an observational multicenter study

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Theory of mind but not emotion perception or neurocognition was associated with QoL in patients. English [32]; Chinese [98]; German [99]; French [100]; Spanish [101]; Italian [102]; Japanese [103]; Persian [104]; Brazilian Portuguese [105].…”

Section: Scz Chronicmentioning

confidence: 99%

European Psychiatric Association guidance on assessment of cognitive impairment in schizophrenia

et al. 2022

View full text Add to dashboard Cite

Background Impairment in a wide range of cognitive abilities has been consistently reported in individuals with schizophrenia. Both neurocognitive and social cognitive deficits are thought to underlie severe functional disabilities associated with schizophrenia. Despite the key role in schizophrenia outcome, cognition is still poorly assessed in both research and clinical settings. Methods In this guidance paper, we provide a systematic review of the scientific literature and elaborate several recommendations for the assessment of cognitive functions in schizophrenia both in research settings and in real-world clinical practice. Results Expert consensus and systematic reviews provided guidance for the optimal assessment of cognitive functions in schizophrenia. Based on the reviewed evidence, we recommend a comprehensive and systematic assessment of neurocognitive and social cognitive domains in schizophrenia, in all phases of the disorder, as well as in subjects at risk to develop psychosis. This European Psychiatric Association guidance recommends not only the use of observer reports but also self-reports and interview-based cognitive assessment tools. The guidance also provides a systematic review of the state of the art of assessment in the first episode of psychosis patients and in individuals at risk for psychosis. Conclusion The comprehensive review of the evidence and the recommendations might contribute to advance the field, allowing a better cognitive assessment, and avoiding overlaps with other psychopathological dimensions. The dissemination of this guidance paper may promote the development of shared guidelines concerning the assessment of cognitive functions in schizophrenia, with the purpose to improve the quality of care and to obtain recovery.

show abstract

“…Cross‐sectional data were drawn from the CSA study, a cohort of 353 in‐ (34.1%) or outpatients (65.9%) aged 55 years or more with an International Classification of Diseases, 10th edition (ICD‐10) diagnosis of schizophrenia (82.4%) or schizoaffective disorder (17.6%). More detailed description of the study methodology can be found elsewhere 25–31 . Participants were recruited between February 2010 and June 2013 from 63 French state hospital psychiatric departments, each of them covering one mutually independent catchment area 32 .…”

Section: Methodsmentioning

confidence: 99%

Late‐onset and nonlate‐onset schizophrenia: A comparison of clinical characteristics in a multicenter study

Kassm

Limosin

Naja

et al. 2021

Int J Geriat Psychiatry

Self Cite

View full text Add to dashboard Cite

Objectives Data are scarce regarding the potential clinical differences between non‐late onset schizophrenia (NLOS, i.e., disorder occurring before 40 years of age), late‐onset schizophrenia (LOS, occurring between ages 40 and 60 years) and very‐late‐onset schizophrenia‐like psychosis (VLOSLP, occurring after 60 years of age). Furthermore, previous research compared LOS patients with non‐age matched NLOS patients. In this study, we sought to examine potential clinical differences between patients of similar age with LOS and NLOS. Methods/Design This is a cross‐sectional multicentre study that recruited in‐ and outpatients older adults (aged ≥55 years) with an ICD‐10 diagnosis of schizophrenia or schizoaffective disorder with NLOS and LOS. Sociodemographic and clinical characteristics, comorbidity, psychotropic medications, quality of life, functioning, and mental health care utilization were drawn for comparison. Results Two hundred seventy‐two participants (79.8%) had NLOS, 61 (17.9%) LOS, and 8 (2.3%) VLOSLP. LOS was significantly and independently associated with greater severity of emotional withdrawal and lower severity of depression (all p < 0.05). However, the magnitude of these associations was modest, with significant adjusted odds ratios ranging from 0.71 to 1.24, and there were no significant between‐group differences in other characteristics. Conclusion In an age‐matched multicenter sample of elderly patients with schizophrenia, older adults with LOS were largely similar to older adults with NLOS in terms of clinical characteristics. The few differences observed may be at least partially related to symptom fluctuation with time. Implications of these findings for pharmacological and nonpharmacological management is yet to be determined.

show abstract

A comprehensive model of predictors of quality of life in older adults with schizophrenia: results from the CSA study

Cited by 11 publications

References 112 publications

Association between FIASMA psychotropic medications and reduced risk of intubation or death in individuals with psychiatric disorders hospitalized for severe COVID-19: an observational multicenter study

Association between FIASMA psychotropic medications and reduced risk of intubation or death in individuals with psychiatric disorders hospitalized for severe COVID-19: an observational multicenter study

European Psychiatric Association guidance on assessment of cognitive impairment in schizophrenia

Late‐onset and nonlate‐onset schizophrenia: A comparison of clinical characteristics in a multicenter study

Contact Info

Product

Resources

About